Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. (21st March 2017)

• Record Type: Journal Article
• Authors: Vandiver, Amy; Girardi, Nicholas; Alhariri, Jihad; Garza, Luis A.
• Is Part Of: International journal of dermatology. Volume 56:Number 8(2017)
• Page Start: 833
• Page End: 835
• Publication Date: 2017-03-21
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/ijd.13598
• Languages: English
• ISSNs: 0011-9059

Abstract

Abstract: Background: Alopecia areata is a relatively common condition affecting patients seen in community dermatology clinics. A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short‐term treatment of alopecia, however little information exists about the long‐term use in otherwise healthy individuals in the community setting. Methods: A patient with chronic alopecia areata and a patient with acute onset alopecia universalis were treated with oral ruxolitinib for over a year. Results: Both patients experienced sustained, near‐complete regrowth without hematologic or other complications after one year of treatment. Oral ruxolitinib effectively and safely treated alopecia in two women. Conclusions: Ruxolitinib should be considered for cases of unresponsive alopecia in the community.